Premature STEMI in Men and Women: Current Clinical Features and Improvements in Management and Prognosis.
Rebeca LorcaIsaac PascualAndrea AparicioAlejandro JuncoRut Alvarez-VelascoNoemi BarjaLuis RocesAlfonso Suárez-CuervoRocio DiazCésar MorísDaniel Hernández-VaqueroPablo AvanzasPublished in: Journal of clinical medicine (2021)
Our results showed a high incidence of cardiovascular risk factors, a high prevalence of SCAD among young women, and a generally good prognosis after standardized treatment. During follow-up, 23% suffered a major cardiovascular event (MACE), without significant differences between sexes and observed survival at 1, 3, and 6 years of follow-up was 96.57% (95% CI 94.04-98.04), 95.64% (95% CI 92.87-97.35), and 94.5% (95% CI 91.12-97.66). An extra effort to prevent/delay STEMI should be invested focusing on smoking avoidance and optimal hypolipemiant treatment both in primary and secondary prevention.